Compare CRESY & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | SGP |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.3M | 799.4M |
| IPO Year | 1997 | 2026 |
| Metric | CRESY | SGP |
|---|---|---|
| Price | $10.88 | $28.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.86 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 205.6K | 71.6K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.96 | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $17.06 |
| 52 Week High | $14.21 | $32.44 |
| Indicator | CRESY | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 61.75 |
| Support Level | $10.52 | $24.85 |
| Resistance Level | $11.74 | $29.92 |
| Average True Range (ATR) | 0.40 | 1.36 |
| MACD | -0.08 | 0.38 |
| Stochastic Oscillator | 1.75 | 97.82 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.